Vaximm reports final Phase I data for VXM01 in recurrent glioblastoma

Vaximm AG (Basel, Switzerland) reported final data from 14 patients with recurrent glioblastoma in a Phase I trial showing that oral VXM01 on days

Read the full 248 word article

User Sign In